The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027.
The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives for animal testing models. However, issues related to the incorporation of organoids into existing workflows are likely to have a negative impact on the growth of the market in the coming years.
Animal models are widely used in biomedical research for human-specific diseases. However, various cases demonstrate that animal models cannot always be predictive for human drug response, for instance, drug toxicology studies. This is because there are wide variations in the metabolism of drugs and toxins in humans compared to animals, which makes it nearly impossible to study drug metabolism in experimental models, such as laboratory rodent species. Additionally, in recent years, several regulations have been implemented that restrict animal use in research activities. Similarly, several bodies, including the Saudi Arabian Ministry of Environment, Water and Agriculture, have banned a series of practices under the new animal cruelty laws. The ban is based on the GCC Animal Welfare Act endorsed by Saudi Arabia.
Therefore, in order to develop alternative testing models, various institutes are involved in developing alternative methods for drug development and biomedical research. As organoids can serve as alternatives to animal models, the current focus on reducing animal use in research is expected to support the growth of the human organoids market.
Based on type, the organoids market has been segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2019, whereas the kidney segment is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the market is segmented into developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology segment held the largest share of the market in 2019; however, the drug discovery and personalized medicine segment is expected to register the highest CAGR in the market during the forecast period. Based on source, the organoids market is segmented into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held the larger share of the market in 2019. The segment is estimated to register the highest CAGR in the market during the forecast period.
Some of the major secondary sources for the Middle East & Africa organoids market included in the report are International Center for Genetic Engineering and Biotechnology, King Faisal University, and World Health Organization.